Kymab, Regeneron antibodies news
Kymab said the English High Court invalidated EU Patents Nos. EP1360287 and EP2264163 from Regeneron protecting VelocImmune mice and humanized mouse antibodies derived from the mice. Kymab said the court stated that the discoveries were unpatentable because they “lack the required evidence that they could be practiced.” Kymab and Regeneron independently engineered mice that have a functional immune system with a larger human Ig sequence component than previous transgenic mice and can be used to produce humanized antibodies. Kymab said that while the decision will only affect patent enforcement in the U.K., the company does not need to produce the humanized antibodies in any other countries. Regeneron said it intends to appeal the decision. ...